What the July 2026 FDA advisory vote actually did.
Seven peptides went before the FDA's Pharmacy Compounding Advisory Committee and six were recommended for the 503A Bulks List. What that recommendation is, what has to happen next, and the four things it is routinely misreported as meaning.
On 23–24 July 2026 the FDA's Pharmacy Compounding Advisory Committee heard seven peptides and voted on whether each should be added to the 503A Bulks List. Six were recommended; one was not. Several of the compounds described elsewhere in this library were among them.
The vote was widely reported, and widely reported badly. It is an advisory recommendation at the start of a rulemaking process, not a decision, not an approval, and not a change in what may lawfully be done with these substances today. This page sets out what happened and, at greater length, what it did not.
What the committee actually voted on
The Pharmacy Compounding Advisory Committee advises the FDA on drug compounding. One of the questions it considers is whether a bulk substance should go on the 503A Bulks List — the list of ingredients a compounding pharmacy operating under section 503A may use to prepare a medicine for an individual patient.
The committee heard four substances on the first day and three on the second, under docket FDA-2025-N-6895. Substances were considered in both free base and acetate forms, and some were listed under names other than the ones in common use: Epithalon was heard as Epitalon, and DSIP as emideltide.
Six of the seven were recommended for the list. Emideltide was the only one the committee declined to recommend. Every vote was divided, several by a single-figure margin.
Recommended
BPC-157, KPV, TB-500, MOTS-C, Semax and Epitalon, each on a divided vote.
Not recommended
Emideltide, the name under which delta sleep-inducing peptide was heard.
Both salt forms
Substances were considered as free base and as acetate, which is how bulk ingredients are actually supplied.
The record
Proceedings sit under FDA docket FDA-2025-N-6895. Vote tallies quoted anywhere, including in the compound notes on this site, are as recorded in published accounts of the meeting; the transcript is the authority.
Four things this vote is not
Each of the following has been asserted in coverage of the meeting. None of them is true, and the distinctions are not technicalities.
- 01
It is not an FDA decision
The committee advises; it does not decide. Its recommendation is not binding, and the agency has to decide whether to accept it. Advisory committee votes are not agency action.
- 02
It is not FDA approval
Addition to the 503A Bulks List is not equivalent to approval of a drug. None of the seven substances is an FDA-approved drug, and a recommendation to permit compounding does not make one.
- 03
It does not make anything legal today
Nothing changes until the FDA completes notice-and-comment rulemaking to formally add a substance to the list. Until then the recommended peptides do not fall within the permitted categories for compounding, whatever the committee advised.
- 04
It is not a finding that these compounds work
The question before the committee concerned suitability as a compounding ingredient. A recommendation is not a conclusion about clinical efficacy, and it does not fill the evidence gaps set out on each compound's own page in this library — MOTS-C, for one, was recommended while having no interventional human administration study at all.
What has to happen next
For any of the recommended substances to become usable in compounding, the FDA has to accept the recommendation and then run a rulemaking process: a proposed rule, a public comment period, and a final rule. That is a matter of many months rather than weeks, and the agency is not obliged to reach the same conclusion the committee did.
Until a final rule exists, the position for each of the six recommended peptides is unchanged from what it was before the meeting. The vote is a signal about direction, not a change in status.
Why this does not change anything about research-use supply
The 503A Bulks List concerns compounding pharmacies preparing medicines for named patients. That is a different activity from the supply of research-use-only material, which is what this site does, and the two are governed separately.
So the vote does not make any compound here approved for human use, does not make it a medicine, and does not alter the research-use-only terms every product on this site is sold under. Everything supplied here remains for laboratory research use only, not for human consumption, diagnosis, treatment, or prevention of any condition.
The reason the meeting is worth a page at all is narrower and more interesting than a change in status: it is a public record of what a panel of experts concluded about the evidence base for seven specific compounds, and the divided votes are themselves informative about how thin that evidence was judged to be.
Common questions.
- Did the FDA approve BPC-157 in July 2026?
No. An advisory committee recommended that BPC-157 be added to the 503A Bulks List, which is the list of ingredients a compounding pharmacy may use. That recommendation is not binding on the FDA, and inclusion on that list is expressly not the same thing as approval of a drug. BPC-157 is not an FDA-approved drug.
- Does the advisory vote make these peptides legal to compound now?
No. The FDA must accept the recommendation and then complete notice-and-comment rulemaking — a proposed rule, a comment period and a final rule — before any substance is formally added. Until that process finishes, the position is unchanged from before the meeting.
- Which peptide did the committee decline to recommend?
Emideltide, the name under which delta sleep-inducing peptide was heard, was the only one of the seven the committee voted against. The other six were recommended, each on a divided vote.
- Why was Epithalon listed as Epitalon on the FDA agenda?
Both spellings are in use for the same tetrapeptide, and the FDA agenda used Epitalon. Several substances were also heard under names other than their common ones, and each was considered in both free base and acetate forms, which is how bulk ingredients are supplied.
- Does a recommendation mean the committee concluded these compounds are effective?
No. The question before the committee concerned suitability as a compounding ingredient, not clinical efficacy. MOTS-C illustrates the gap: it was recommended despite there being no interventional study in which it was administered to humans.
- Does this change the status of research-use-only material?
No. The 503A Bulks List governs compounding pharmacies preparing medicines for individual patients, which is a separate activity from research-use-only supply and is regulated separately. Nothing about the vote makes any of these substances approved for human use.